Gel could treat viral eye infection

Tampa-Sirion Therapeutics Inc. has made an exclusive licensing agreement with Laboratoires Thea of France for U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for treating certain viral and superficial eye infections.

Related Videos
Related Content

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Over time, markets have proved positive and resilient

March 17th 2023

LumiThera announces sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Over time, markets have proved positive and resilient

March 17th 2023

LumiThera announces sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

The challenges of tube shunts in pediatric glaucoma surgery

March 20th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Over time, markets have proved positive and resilient

March 17th 2023

LumiThera announces sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023
© 2023 MJH Life Sciences

All rights reserved.